Dyck G, Maayah Z, Eurich D, Dyck J
Schizophr Bull Open. 2024; 3(1):sgab053.
PMID: 39144756
PMC: 11205871.
DOI: 10.1093/schizbullopen/sgab053.
Wenzel J, Badde L, Haas S, Bonivento C, Van Rheenen T, Antonucci L
Neuropsychopharmacology. 2023; 49(3):573-583.
PMID: 37737273
PMC: 10789737.
DOI: 10.1038/s41386-023-01729-7.
Purcell J, Brown J, Tullar R, Bloomer B, Kim D, Moussa-Tooks A
Schizophr Bull. 2023; 49(3):726-737.
PMID: 36869757
PMC: 10154703.
DOI: 10.1093/schbul/sbac206.
Ba Z, Chen M, Lai J, Liao Y, Fang H, Lu D
Front Psychiatry. 2022; 13:900757.
PMID: 36203826
PMC: 9530893.
DOI: 10.3389/fpsyt.2022.900757.
Romanowska S, Best M, Bowie C, Depp C, Patterson T, Penn D
Schizophr Res Cogn. 2022; 29:100254.
PMID: 35521291
PMC: 9062312.
DOI: 10.1016/j.scog.2022.100254.
Lifespan evolution of neurocognitive impairment in schizophrenia - A narrative review.
Fett A, Reichenberg A, Velthorst E
Schizophr Res Cogn. 2022; 28:100237.
PMID: 35242606
PMC: 8861413.
DOI: 10.1016/j.scog.2022.100237.
Characterising Demographic, Clinical and Functional Features of Cognitive Subgroups in Schizophrenia Spectrum Disorders: A Systematic Review.
Carruthers S, Van Rheenen T, Karantonis J, Rossell S
Neuropsychol Rev. 2021; 32(4):807-827.
PMID: 34694542
DOI: 10.1007/s11065-021-09525-0.
Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial.
Leweke F, Rohleder C, Gerth C, Hellmich M, Pukrop R, Koethe D
Front Pharmacol. 2021; 12:614811.
PMID: 33995015
PMC: 8117353.
DOI: 10.3389/fphar.2021.614811.
Toolkit for assessing and addressing cognitive health in early psychosis: Evaluation of feasibility and utility in a coordinated specialty care setting.
Saperstein A, Medalia A, Malinovsky I, Bello I, Dixon L
Early Interv Psychiatry. 2020; 15(5):1376-1381.
PMID: 33185025
PMC: 8272079.
DOI: 10.1111/eip.13070.
Clinical Neuropsychology as a Specialist Profession in European Health Care: Developing a Benchmark for Training Standards and Competencies Using the Europsy Model?.
Hokkanen L, Barbosa F, Ponchel A, Constantinou M, Kosmidis M, Varako N
Front Psychol. 2020; 11:559134.
PMID: 33123042
PMC: 7573555.
DOI: 10.3389/fpsyg.2020.559134.
Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations
.
McCleery A, Nuechterlein K
Dialogues Clin Neurosci. 2019; 21(3):239-248.
PMID: 31749648
PMC: 6829172.
DOI: 10.31887/DCNS.2019.21.3/amccleery.
The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia.
Cotter J, Barnett J, Granger K
Front Psychiatry. 2019; 10:648.
PMID: 31551837
PMC: 6743013.
DOI: 10.3389/fpsyt.2019.00648.
Development and testing of a web-based battery to remotely assess cognitive health in individuals with schizophrenia.
Biagianti B, Fisher M, Brandrett B, Schlosser D, Loewy R, Nahum M
Schizophr Res. 2019; 208:250-257.
PMID: 30733167
PMC: 6544475.
DOI: 10.1016/j.schres.2019.01.047.
A comparison between the Mini-Mental State Examination and the Montreal Cognitive Assessment Test in schizophrenia.
Rademeyer M, Joubert P
S Afr J Psychiatr. 2018; 22(1):890.
PMID: 30263162
PMC: 6138136.
DOI: 10.4102/sajpsychiatry.v22i1.890.
Long-term cognitive trajectories and heterogeneity in patients with schizophrenia and their unaffected siblings.
Islam M, Habtewold T, van Es F, Quee P, van den Heuvel E, Alizadeh B
Acta Psychiatr Scand. 2018; 138(6):591-604.
PMID: 30242827
PMC: 6220939.
DOI: 10.1111/acps.12961.
Neurocognitive profiles in the prodrome to psychosis in NAPLS-1.
Velthorst E, Meyer E, Giuliano A, Addington J, Cadenhead K, Cannon T
Schizophr Res. 2018; 204:311-319.
PMID: 30078717
PMC: 6359987.
DOI: 10.1016/j.schres.2018.07.038.
Neurocognitive normality in schizophrenia revisited.
Heinrichs R, Pinnock F, Muharib E, Hartman L, Goldberg J, McDermid Vaz S
Schizophr Res Cogn. 2017; 2(4):227-232.
PMID: 29114464
PMC: 5609644.
DOI: 10.1016/j.scog.2015.09.001.
Validation of the cognitively normal range and below normal range subtypes in chronically hospitalized patients with schizophrenia.
Chiang S, Ni C, Tsai C, Lin K
Schizophr Res Cogn. 2017; 5:28-34.
PMID: 28740814
PMC: 5514302.
DOI: 10.1016/j.scog.2016.06.002.
Deviation from expected cognitive ability across psychotic disorders.
Hochberger W, Combs T, Reilly J, Bishop J, Keefe R, Clementz B
Schizophr Res. 2017; 192:300-307.
PMID: 28545944
PMC: 5699979.
DOI: 10.1016/j.schres.2017.05.019.
Cortical Thinning in Network-Associated Regions in Cognitively Normal and Below-Normal Range Schizophrenia.
Heinrichs R, Pinnock F, Parlar M, Hawco C, Hanford L, Hall G
Schizophr Res Treatment. 2017; 2017:9760905.
PMID: 28348889
PMC: 5350425.
DOI: 10.1155/2017/9760905.